When Concentra bought iTeos earlier this year, the headline number—$10.047 per share—looked underwhelming. In fact, it was at a slight discount to what the stock was trading at the day before. But buried in the fine print was something intriguing: a non‑transferable contingent value right (CVR) promising iTeos shareholders maybe more later if the company … Continue reading Why Biotech Deals Keep Coming with CVRs